BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20647330)

  • 1. BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.
    Galmiche A; Ezzoukhry Z; François C; Louandre C; Sabbagh C; Nguyen-Khac E; Descamps V; Trouillet N; Godin C; Regimbeau JM; Joly JP; Barbare JC; Duverlie G; Mazière JC; Chatelain D
    Mol Cancer Res; 2010 Aug; 8(8):1116-25. PubMed ID: 20647330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Bcl-2 homology domain 3 (BH3) mimetic ABT-737 reveals the dynamic regulation of bad, a proapoptotic protein of the Bcl-2 family, by Bcl-xL.
    Ezzoukhry Z; Louandre C; François C; Saidak Z; Godin C; Mazière JC; Galmiche A
    Mol Pharmacol; 2011 Jun; 79(6):997-1004. PubMed ID: 21393385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma.
    Chiou JF; Tai CJ; Huang MT; Wei PL; Wang YH; An J; Wu CH; Liu TZ; Chang YJ
    Ann Surg Oncol; 2010 Feb; 17(2):603-12. PubMed ID: 19830497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
    Chen HC; Jeng YM; Yuan RH; Hsu HC; Chen YL
    Ann Surg Oncol; 2012 Jun; 19(6):2011-9. PubMed ID: 22146883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
    Schulze-Bergkamen H; Fleischer B; Schuchmann M; Weber A; Weinmann A; Krammer PH; Galle PR
    BMC Cancer; 2006 Oct; 6():232. PubMed ID: 17014711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bid sensitizes apoptosis induced by chemotherapeutic drugs in hepatocellular carcinoma.
    Miao J; Chen GG; Chun SY; Chak EC; Lai PB
    Int J Oncol; 2004 Sep; 25(3):651-9. PubMed ID: 15289866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
    Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
    J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
    Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
    Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
    Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
    Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Miyagi T; Hosui A; Tatsumi T; Ishida H; Noda T; Nagano H; Doki Y; Mori M; Hayashi N
    J Hepatol; 2010 May; 52(5):698-704. PubMed ID: 20347499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells.
    Cheng AS; Chan HL; Leung WK; Wong N; Johnson PJ; Sung JJ
    Int J Oncol; 2003 Jul; 23(1):113-9. PubMed ID: 12792783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma.
    Ikeguchi M; Hirooka Y; Kaibara N
    Cancer; 2002 Nov; 95(9):1938-45. PubMed ID: 12404288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis.
    Li XF; Gong RY; Wang M; Yan ZL; Yuan B; Wang K; Shi LH
    Biochem Biophys Res Commun; 2012 Feb; 418(3):531-6. PubMed ID: 22285185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
    Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenovirus vector expressing mda-7 selectively kills hepatocellular carcinoma cell line Hep3B.
    Xue XB; Chen K; Wang CJ; Zheng JW; Yu Y; Peng ZH; Wu ZD
    Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):509-14. PubMed ID: 18842498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.
    Busche S; John K; Wandrer F; Vondran FWR; Lehmann U; Wedemeyer H; Essmann F; Schulze-Osthoff K; Bantel H
    Cell Death Dis; 2021 Jul; 12(8):736. PubMed ID: 34312366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.